Patents Assigned to IPCA Laboratories Limited
  • Anti-thrombotic compounds
    Patent number: 10105353
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: October 23, 2018
    Assignee: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki Moje
  • Methods for the treatment or prophylaxis of thrombosis or embolism
    Patent number: 9321785
    Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: April 26, 2016
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Nellithanath Thankachen Byju
  • PHARMACEUTICAL COMBINATION
    Publication number: 20140128402
    Abstract: The present invention discloses a pharmaceutical combination comprising Hydroxychloroquine and a DPP-IV inhibitor or their pharmaceutically acceptable salts, solvates or prodrugs thereof, for preventing, slowing the progression of, delaying, improving, restoring, or treating a condition or a disease resulting from metabolic disorders.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: IPCA Laboratories Limited
    Inventors: Anil PAREEK, Gopakumar G. NAIR
  • Anti-Thrombotic Compounds
    Publication number: 20140038924
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Application
    Filed: October 3, 2013
    Publication date: February 6, 2014
    Applicant: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki MOJE
  • Anti-Thrombotic Compounds
    Publication number: 20140031320
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki MOJE
  • METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM
    Publication number: 20140018331
    Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.
    Type: Application
    Filed: August 7, 2013
    Publication date: January 16, 2014
    Applicant: IPCA Laboratories Limited
    Inventors: Ashok KUMAR, Nellithanath Thankachen Byju
  • Anti-Thrombotic Compounds
    Publication number: 20130316987
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 28, 2013
    Applicant: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki MOJE
  • Anti-Thrombotic Compounds
    Publication number: 20130316986
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 28, 2013
    Applicant: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki MOJE
  • Methods for the treatment or prophylaxis of thrombosis or embolism
    Patent number: 8541422
    Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: September 24, 2013
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Nellithanath Thankachen Byju
  • Solid forms of methyl (7aS,2?S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate
    Patent number: 8536337
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: September 17, 2013
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki Moje
  • Pharmaceutical compositions for the treatment of diabetes mellitus
    Patent number: 8415360
    Abstract: Disclosed herein is a pharmaceutical composition comprising Hydroxychloroquine or its pharmaceutically acceptable salt and at least one antidiabetic compound, useful in the treatment of diabetes mellitus.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: April 9, 2013
    Assignee: IPCA Laboratories Limited
    Inventor: Anil Pareek
  • METHODS FOR THE TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISM
    Publication number: 20120053157
    Abstract: The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.
    Type: Application
    Filed: August 26, 2011
    Publication date: March 1, 2012
    Applicant: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Nellithanath Thankachen Byju
  • Process for preparation of atovaquone and novel intermediates thereof
    Patent number: 7847127
    Abstract: Disclosed herein is a novel process for preparation of atovaquone. The process includes reacting 1,4-naphthoquinone with trans-4-(4-chlorophenyl) cyclohexane carboxylic acid followed by halogenation to obtain a dihalo-compound. Further, dehydrohalogenation of the dihalo-compound produces a monohalogeno-compound which under goes hydrolysis to produce atovaquone. The invention also discloses atovaquone in a substantially pure and well defined polymorphic form designated as “Form IPCA-ATO,” and the preparation thereof.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: December 7, 2010
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Suneel Yeshwant Dike, Pramil Kumar Mathur, Nellithanath Thankachen Byju, Brajesh Sharma, Swapnil Shreekant Kore, Vitthal Suryabhan Buchude, Dharmendra Singh
  • Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine
    Patent number: 7847094
    Abstract: Disclosed herein is an industrial preparation of Quetiapine by the reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine or its salt with 2-(2-chloroethoxy)ethanol in presence of an organic or inorganic base under neat or aqueous condition to form 11-[4-{2-(2-hydroxyethoxy)ethyl}-1-piperazinyl]dibenzo[b,f]-[1,4]thiazepine. The quetiapine free base obtained is further converted to its hemi-fumarate salt.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: December 7, 2010
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Dharmendra Singh, Swapnali Hemant Patil, Ganesh Devidas Mahale, Uttamrao Arjunrao Sawant, Balasaheb Ganpat Jadhav, Ragneshkumar Rana
  • Process for preparation of highly pure isotretinoin
    Patent number: 7763748
    Abstract: The present invention relates to a process for preparation of isotretinoin and more specifically, to a purification process for obtaining highly pure isotretinoin that is useful as a keratolytic agent, particularly useful for the treatment of acne. The process involves treating isotretinoin containing metal contamination and/or other impurities with a base in a suitable solvent to form a solution of isotretinoin, followed by adsorption, precipiation, and filtration or centrifugation.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: July 27, 2010
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Dharmendra Singh, Ganesh Devidas Mahale, Ragnesh Kumar Rana, Mahesh Kharade
  • Process for the synthesis of Losartan potassium
    Patent number: 7345071
    Abstract: Improved processes using primary, secondary and tertiary alcohols and with safer mode of introduction of the reagent and reaction conditions are described. Further, the process of manufacture of Losartan potassium by use of alkali metal salt such as Potassium carbonate is disclosed. A process for preparation of the polymorphic Form I of Losartan potassium is also disclosed herein.
    Type: Grant
    Filed: August 5, 2004
    Date of Patent: March 18, 2008
    Assignee: IPCA Laboratories Limited
    Inventors: Ashok Kumar, Rajesh Kumar Keshava Prasad Singh, Nalinakshya Balaram Panda, Abhay Atmaram Upare, Manmohan Madhavrao Nimbalkar, Satish Rajanikant Soudagar, Ashvini Kumar Nand Kishore Saxena